WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections
WuXi AppTec announced that its Active Pharmaceutical Ingredient (API) manufacturing sites in Changzhou and Taixing, China, have successfully passed U.S. FDA inspections in March 2025 with no observations or Form 483 issues.
The Changzhou facility's GMP surveillance inspection covered 21 FDA-approved products, while Taixing completed a Pre-Approval Inspection for commercial manufacturing of a peptide-based therapeutic. The 169-acre Taixing site, operational since September 2023, is the company's newest and largest API manufacturing facility.
WuXi AppTec is expanding globally with recent developments including:
- Doubled oral dose capacity at Couvet, Switzerland facility in 2024
- Ongoing construction of Middletown, Delaware site (operations expected by 2026)
- New Singapore R&D and manufacturing site groundbreaking (Phase I operations planned for 2027)
WuXi AppTec ha annunciato che i suoi siti di produzione di Ingredienti Farmaceutici Attivi (API) a Changzhou e Taixing, in Cina, hanno superato con successo le ispezioni della FDA degli Stati Uniti nel marzo 2025, senza osservazioni o problemi con il modulo 483.
L'ispezione di sorveglianza GMP della struttura di Changzhou ha coperto 21 prodotti approvati dalla FDA, mentre Taixing ha completato un'Ispezione Pre-Approva per la produzione commerciale di un terapeutico a base di peptide. Il sito di Taixing, che si estende su 169 acri e operativo da settembre 2023, è il più recente e il più grande impianto di produzione di API dell'azienda.
WuXi AppTec sta espandendo la sua presenza globale con sviluppi recenti che includono:
- Capacità di dosaggio orale raddoppiata presso l'impianto di Couvet, in Svizzera, nel 2024
- Costruzione in corso del sito di Middletown, Delaware (operazioni previste entro il 2026)
- Inizio dei lavori per un nuovo sito di R&S e produzione a Singapore (operazioni della Fase I previste per il 2027)
WuXi AppTec anunció que sus sitios de fabricación de Ingredientes Farmacéuticos Activos (API) en Changzhou y Taixing, China, han pasado con éxito las inspecciones de la FDA de EE. UU. en marzo de 2025, sin observaciones ni problemas con el Formulario 483.
La inspección de vigilancia GMP de la instalación de Changzhou cubrió 21 productos aprobados por la FDA, mientras que Taixing completó una Inspección Pre-Aprobación para la fabricación comercial de un terapéutico basado en péptidos. El sitio de Taixing, que abarca 169 acres y está en operación desde septiembre de 2023, es la instalación de fabricación de API más nueva y grande de la empresa.
WuXi AppTec está expandiéndose globalmente con desarrollos recientes que incluyen:
- Capacidad de dosis oral duplicada en la instalación de Couvet, Suiza, en 2024
- Construcción en curso del sitio de Middletown, Delaware (se espera que las operaciones comiencen en 2026)
- Inicio de la construcción de un nuevo sitio de I+D y fabricación en Singapur (se prevé que las operaciones de la Fase I comiencen en 2027)
우시 앱텍은 중국 창저우와 타이싱에 있는 활성 제약 성분(API) 제조 시설이 2025년 3월 미국 FDA 검사를 성공적으로 통과했으며, 관찰 사항이나 483 양식 문제 없이 진행되었다고 발표했습니다.
창저우 시설의 GMP 감시 검사에서는 FDA 승인을 받은 21개 제품이 포함되었으며, 타이싱은 펩타이드 기반 치료제의 상업 제조를 위한 사전 승인 검사를 완료했습니다. 169에이커 규모의 타이싱 사이트는 2023년 9월부터 운영되고 있으며, 회사의 최신이자 가장 큰 API 제조 시설입니다.
우시 앱텍은 최근의 발전을 통해 글로벌 확장을 진행 중입니다. 여기에는:
- 2024년 스위스 쿠베에서 경구 용량을 두 배로 증가
- 델라웨어 미들타운 사이트의 건설 진행 중(2026년 운영 예정)
- 싱가포르에서의 새로운 연구개발 및 제조 사이트 착공(1단계 운영이 2027년 예정)
WuXi AppTec a annoncé que ses sites de fabrication d'Ingrédients Pharmaceutiques Actifs (API) à Changzhou et Taixing, en Chine, ont réussi les inspections de la FDA américaine en mars 2025, sans observations ni problèmes avec le formulaire 483.
L'inspection de surveillance GMP de l'installation de Changzhou a couvert 21 produits approuvés par la FDA, tandis que Taixing a complété une Inspection Pré-Autorisation pour la fabrication commerciale d'un thérapeutique à base de peptide. Le site de Taixing, s'étendant sur 169 acres et opérationnel depuis septembre 2023, est le plus récent et le plus grand site de fabrication d'API de l'entreprise.
WuXi AppTec s'étend à l'échelle mondiale avec des développements récents comprenant :
- Capacité de dosage oral doublée à l'installation de Couvet, en Suisse, en 2024
- Construction en cours du site de Middletown, Delaware (les opérations devraient débuter en 2026)
- Début de la construction d'un nouveau site de R&D et de fabrication à Singapour (les opérations de la phase I sont prévues pour 2027)
WuXi AppTec gab bekannt, dass seine Produktionsstätten für aktive pharmazeutische Inhaltsstoffe (API) in Changzhou und Taixing, China, im März 2025 erfolgreich die FDA-Inspektionen der USA bestanden haben, ohne Beobachtungen oder Probleme mit dem Formular 483.
Die GMP-Überwachungsinspektion der Einrichtung in Changzhou umfasste 21 von der FDA genehmigte Produkte, während Taixing eine Vorabgenehmigungsinspektion für die kommerzielle Herstellung eines peptidbasierten Therapeutik abgeschlossen hat. Das 169 Hektar große Gelände in Taixing, das seit September 2023 in Betrieb ist, ist die neueste und größte API-Produktionsstätte des Unternehmens.
WuXi AppTec expandiert global mit aktuellen Entwicklungen, die Folgendes umfassen:
- Verdopplung der oralen Dosierungskapazität in der Anlage in Couvet, Schweiz, im Jahr 2024
- Fortschreitender Bau des Standorts Middletown, Delaware (Betrieb wird für 2026 erwartet)
- Baubeginn eines neuen Forschungs- und Entwicklungs- sowie Produktionsstandorts in Singapur (Betrieb der Phase I ist für 2027 geplant)
- Successfully passed FDA inspections at two major API manufacturing sites with zero observations
- Operational approval for commercial manufacturing of peptide-based therapeutic at Taixing facility
- Significant global expansion with new facilities in Switzerland, USA, and Singapore
- Portfolio includes 21 FDA-approved products at Changzhou facility
- None.
The Company's API site at
On March 21, 2025, the API site at Taixing also completed a Pre-Approval Inspection (PAI) for the commercial manufacturing of a peptide-based therapeutic, with no observation. The site presented its state-of-the-art infrastructure, the team's strong technical expertise, and the high level of compliance demonstrated through its systems, documentation, and records. Operational since September 2023, the 169-acre Taixing site is the company's newest and largest API manufacturing facility. The successful inspection confirms the site's readiness to support commercial API supply to the global market.
"Our team's consistent focus on quality and compliance is key to enabling our global partners," said Dr. Minzhang Chen, Co-CEO of WuXi AppTec. "We're pleased that both the
The
WuXi AppTec continues to invest in capacity expansion to meet growing global demand. The company's investment in its Couvet,
About WuXi AppTec
As a global company with operations across
View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-apptecs-changzhou-and-taixing-api-sites-successfully-pass-fda-inspections-302415884.html
SOURCE WuXi AppTec